Reported cases of a switch in phenotype following immunotherapy
| Reference . | Number of patients . | Age . | Molecular characteristics . | Treatment . | Time of switch . |
|---|---|---|---|---|---|
| 6 | 2 | 1 Infant, 1 adult | MLL-rearranged, ins(11;10); (t4;11) | CD19-CAR T cells | D21/D22 |
| 7 | 1 | Infant | MLL-rearranged t(4;11) | Blinatumomab | D15 |
| 5 | 1 | Infant | MLL-rearranged | CD19-CAR T cells | Not reported |
| 8 | 1 | 8 y | None | Blinatumomab | D21 |
| 9 | 1 | 15 y | MLL-rearranged, t(4;11) | Blinatumomab | D28 |
| 11 | 1 | 40 y | MLL-rearranged, t(4;11) | Blinatumomab | D9 |
| 10 | 2 | 66 y/73 y | t(9;22)(q34;q11) | Blinatumomab | Third cycle/not reported |
| Reference . | Number of patients . | Age . | Molecular characteristics . | Treatment . | Time of switch . |
|---|---|---|---|---|---|
| 6 | 2 | 1 Infant, 1 adult | MLL-rearranged, ins(11;10); (t4;11) | CD19-CAR T cells | D21/D22 |
| 7 | 1 | Infant | MLL-rearranged t(4;11) | Blinatumomab | D15 |
| 5 | 1 | Infant | MLL-rearranged | CD19-CAR T cells | Not reported |
| 8 | 1 | 8 y | None | Blinatumomab | D21 |
| 9 | 1 | 15 y | MLL-rearranged, t(4;11) | Blinatumomab | D28 |
| 11 | 1 | 40 y | MLL-rearranged, t(4;11) | Blinatumomab | D9 |
| 10 | 2 | 66 y/73 y | t(9;22)(q34;q11) | Blinatumomab | Third cycle/not reported |